Download PDF
Semin Liver Dis 2004; 24(2): 127-137
DOI: 10.1055/s-2004-828890
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The Molecular Pathogenesis of Cholangiocarcinoma

Eric P. Berthiaume1 , Jack Wands2
  • 1Fellow in Gastroenterology, Brown Medical Schoo, Providence, Rhode Island
  • 2Professor, Rhode Island Hospital and Brown Medical School, Providence, Rhode Island
Further Information

Publication History

Publication Date:
11 June 2004 (online)

    Permissions and Reprints

Cholangiocarcinoma is rising in clinical importance because of increasing incidence, poor prognosis, and suboptimal response to therapy. Recent investigations into the underlying molecular mechanisms involved in cholangiocarcinogenesis and tumor growth have contributed greatly to our understanding of this disease. To review this topic, we discuss the molecular mechanisms in sections reflecting the unique features that allow cancer cells to develop and maintain a growth advantage. Through a better understanding of these mechanisms, improved and more specific diagnostic, therapeutic, and preventative strategies may be developed and hopefully improve the outcome of this devastating disease.

KEYWORDS

Cholangiocarcinoma - biliary carcinogenesis - apoptosis - metastasis

REFERENCES

  • 1 Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.  Hepatology. 2001;  33 1353-1357
    CrossrefPubMedGoogle Scholar
  • 2 Taylor-Robinson S D, Toledano M B, Arora S et al.. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.  Gut. 2001;  48 816-820
    CrossrefPubMedGoogle Scholar
  • 3 Davila J A, El-Serag H D. Cholangiocarcinoma: the “other” liver cancer on the rise.  Am J Gastroenterol. 2002;  97 3199-3200
    PubMedGoogle Scholar
  • 4 Gores G. Cholangiocarcinoma: current concepts and insights.  Hepatology. 2003;  37 961-969
    CrossrefPubMedGoogle Scholar
  • 5 Khan S A, Davidson B R, Goldin R et al.. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.  Gut. 2002;  51 vi1-vi9
    PubMedGoogle Scholar
  • 6 Piet C DG, Gores G, LaRusso N et al.. Biliary tract cancers.  N Engl J Med. 1999;  341 1368-1378
    CrossrefPubMedGoogle Scholar
  • 7 Chapman R. Risk factors for biliary tract carcinogenesis.  Ann Oncol. 1999;  10(Suppl 4) 308-311
    CrossrefPubMedGoogle Scholar
  • 8 Hanahan D, Weinberg R A. The hallmarks of cancer.  Cell. 2000;  100 57-70
    CrossrefPubMedGoogle Scholar
  • 9 Liu Z, Sakamoto T, Ezure T et al.. Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type 1 ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium.  Hepatology. 1998;  28 1260-1268
    CrossrefPubMedGoogle Scholar
  • 10 Matsumoto K, Fujii H, Michalopoulos G et al.. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro.  Hepatology. 1994;  20 376-382
    CrossrefPubMedGoogle Scholar
  • 11 Park J, Tadlock L, Gores G J, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line.  Hepatology. 1999;  30 1128-1133
    Google Scholar
  • 12 Yokomuro S, Tsuji H, Lunz J G et al.. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic bilieary epithelial cells.  Hepatology. 2000;  32 26-35
    CrossrefPubMedGoogle Scholar
  • 13 Yokomuro S, Lunz J G, Sakamoto T et al.. The effect of interleukin-6(IL-6)/gp130 signaling on biliary epithelial cell growth, in vitro.  Cytokine. 2000;  12 727-730
    CrossrefPubMedGoogle Scholar
  • 14 Sugawara H, Yasoshima M, Katayanagi K et al.. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma.  Histopathology. 1998;  33 145-153
    CrossrefPubMedGoogle Scholar
  • 15 Heinrich P C, Behrmann I, Serge H et al.. Principles of interleukin (IL)-6-type cytokine signaling and its regulation.  Biochem J. 2003;  374 1-20
    CrossrefPubMedGoogle Scholar
  • 16 Yasohima M, Kono N, Sugawara H et al.. Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: in situ and culture study.  Lab Invest. 1998;  78 89-100
    PubMedGoogle Scholar
  • 17 Goydos J S, Brumfield A M, Frezza E et al.. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker.  Ann Surg. 1998;  227 398-404
    CrossrefPubMedGoogle Scholar
  • 18 Okada K, Shimizu Y, Nambu S et al.. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line.  J Gastroenterol Hepatol. 1994;  9 462-467
    PubMedGoogle Scholar
  • 19 Wu T, Han C, Lunz J G et al.. Involvement of 85-kd cytosolic phospholipase a2 and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells.  Hepatology. 2002;  36 363-373
    CrossrefPubMedGoogle Scholar
  • 20 Boccaccio C, Gaudino G, Gambarotta G et al.. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF.  J Biol Chem. 1994;  269 12846-12851
    PubMedGoogle Scholar
  • 21 Lai G-H, Radaeva S, Nakamura T, Sirica A E. Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasia and associated ‘intestinal-type’ biliary cancer chemically induced in rat liver.  Hepatology. 2000;  31 1257-1265
    CrossrefPubMedGoogle Scholar
  • 22 Radaeva S, Ferreira-Gonzalez A, Sirica A E. Overexpression of c-Neu and c-Met during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.  Hepatology. 1999;  29 1453-1462
    CrossrefPubMedGoogle Scholar
  • 23 Aishima S I, Taguchi K I, Sugimachi K et al.. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.  Histopathology. 2002;  40 269-278
    CrossrefPubMedGoogle Scholar
  • 24 Harada K, Terada T, Nakanuma Y. Detection of transforming growth factor-alpha protein and messenger RNA in hepatobiliary diseases by immunohistochemical and in situ hybridization techniques.  Hum Pathol. 1996;  27 787-792
    CrossrefPubMedGoogle Scholar
  • 25 Ito Y, Takeda T, Sasaki Y et al.. Expression and clinical significance of the erbB family in intrahepatic cholangiocarcinoma.  Pathol Res Pract. 2001;  197 95-100
    PubMedGoogle Scholar
  • 26 Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.  Cell. 2002;  110 669-672
    CrossrefPubMedGoogle Scholar
  • 27 Collier J D, Guo K, Mathew J et al.. c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarinoma.  J Hepatol. 1992;  14 377-380
    CrossrefPubMedGoogle Scholar
  • 28 Terada T, Ashida K, Endo K et al.. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma.  Histopathology. 1998;  33 325-331
    CrossrefPubMedGoogle Scholar
  • 29 Sirica A E, Radaeva S, Caran N. NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.  Am J Pathol. 1997;  151 1685-1694
    PubMedGoogle Scholar
  • 30 Kiguchi K, Carbajal S, Chan K et al.. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma.  Cancer Res. 2001;  61 6971-6976
    Google Scholar
  • 31 DuBois R N, Radhika A, Reddy B S, Entingh A J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.  Gastroenterology. 1996;  110 1259-1262
    PubMedGoogle Scholar
  • 32 Shirvani V, Ouatu-Lascar R, Kaur B S et al.. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure.  Gastroenterology. 2000;  118 487-496
    PubMedGoogle Scholar
  • 33 Eberhart C E, Coffey R J, Radhika A et al.. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas.  Gastroenterology. 1994;  107 1183-1188
    PubMedGoogle Scholar
  • 34 Williams C S, Mann M, Dubois R N. The role of cyclooxygenases in inflammation, cancer and development.  Oncogene. 1999;  18 7908-7916
    PubMedGoogle Scholar
  • 35 Chariyalertsak S, Sirikulchayanonta V, Mayer D et al.. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.  Gut. 2001;  48 80-86
    CrossrefPubMedGoogle Scholar
  • 36 Endo K, Yoon B-I, Pairojkul C et al.. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.  Hepatology. 2002;  36 439-450
    CrossrefPubMedGoogle Scholar
  • 37 Hayashi N, Yamamoto H, Hiraoka N et al.. Differential expression of cyclooxygenase-2 in human bile duct epithelial cells and bile duct neoplasm.  Hepatology. 2001;  34 638-650
    CrossrefPubMedGoogle Scholar
  • 38 Shimonishi T, Isse K, Shibata F et al.. Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.  Hepatology. 2000;  32 761-769
    CrossrefPubMedGoogle Scholar
  • 39 Yoon J-H, Higuchi H, Werneburg N W et al.. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.  Gastroenterology. 2002;  122 985-993
    Google Scholar
  • 40 Sirica A E, Lai G-H, Endo K et al.. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets.  Semin Liver Dis. 2002;  22 303-313
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Kang Y K, Kim W H, Lee H W et al.. Mutation of p53 and k-ras and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.  Lab Invest. 1999;  79 477-483
    PubMedGoogle Scholar
  • 42 Ohashi K, Nakajima Y, Kanehiro H et al.. K-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinoma: relation to gross tumor morphology.  Gastroenterology. 1995;  109 1612-1617
    CrossrefPubMedGoogle Scholar
  • 43 Tada M, Omata M, Ohto M. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma.  Cancer. 1992;  69 1115-1118
    PubMedGoogle Scholar
  • 44 Tannapfel A, Benicke M, Katalinic A et al.. Frequency of p16-INK4A alteration and k-ras mutations in intrahepatic cholangiocarcinoma of the liver.  Gut. 2000;  47 721-727
    CrossrefPubMedGoogle Scholar
  • 45 Su W C, Shiesh S C, Liu H S et al.. Expression of oncogene products HER2/neu and ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders.  Dig Dis Sci. 2001;  46 1387-1392
    CrossrefPubMedGoogle Scholar
  • 46 Jaiswal M, LaRusso N F, Burgart L J, Gores G J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism.  Cancer Res. 2000;  60 184-190
    Google Scholar
  • 47 Evan G I, Vousden K H. Proliferation, cell cycle and apoptosis in cancer.  Nature. 2001;  411 342-348
    CrossrefPubMedGoogle Scholar
  • 48 Levine A. p53, the cellular gatekeeper for growth and division.  Cell. 1997;  88 323-331
    PubMedGoogle Scholar
  • 49 Sturm P D, Baas I O, Clement M J et al.. Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinoma from a high-incidence area.  Int J Cancer. 1998;  78 695-698
    CrossrefPubMedGoogle Scholar
  • 50 Tannapfel A, Weinans L, Geibler F et al.. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver.  Dig Dis Sci. 2000;  45 317-324
    CrossrefPubMedGoogle Scholar
  • 51 Furubo S, Harada K, Shimonishi T et al.. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.  Histopathology. 1999;  35 230-240
    CrossrefPubMedGoogle Scholar
  • 52 Tannapfel A, Engeland K, Weinans L et al.. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver.  Br J Cancer. 1999;  80 1069-1074
    CrossrefPubMedGoogle Scholar
  • 53 Taniai M, Higuchi H, Burgart L J, Gores G J. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma.  Gastroenterology. 2002;  123 1090-1098
    CrossrefPubMedGoogle Scholar
  • 54 Tannapfel A, Sommerer F, Benicke M et al.. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma.  J Pathol. 2002;  197 624-631
    CrossrefPubMedGoogle Scholar
  • 55 Ahrendt S A, Eisenberger C F, Yip L et al.. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.  J Surg Res. 1999;  84 88-93
    CrossrefPubMedGoogle Scholar
  • 56 Green D R, Reed J C. Mitochondria and apoptosis.  Science. 1998;  281 1309-1312
    CrossrefPubMedGoogle Scholar
  • 57 Hengartner M. The biochemistry of apoptosis.  Nature. 2000;  407 770-776
    CrossrefPubMedGoogle Scholar
  • 58 Kaufmann S H, Gores G J. Apoptosis and cancer.  Bioessays. 2000;  22 1007-1017
    CrossrefPubMedGoogle Scholar
  • 59 Que F G, Phan V A, Phan V H et al.. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.  Hepatology. 1999;  30 1398-1404
    CrossrefPubMedGoogle Scholar
  • 60 Torok N J, Higuchi H, Bronk S, Gores G J. Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9.  Cancer Res. 2002;  62 1648-1653
    PubMedGoogle Scholar
  • 61 Charlotte F, L'Hermine A, Martin N et al.. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver.  Am J Pathol. 1994;  144 460-465
    PubMedGoogle Scholar
  • 62 Harnois G M, Que F G, LaRusso N F, Gores G J. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line.  Hepatology. 1997;  26 884-890
    PubMedGoogle Scholar
  • 63 Okaro A C, Deery A R, Hutchins R R, Davidson B R. The expression of antiapoptotic proteins Bcl-2, Bcl-Xl, and Mcl-1 in benign, dysplastic and malignant biliary epithelium.  J Clin Pathol. 2001;  54 927-932
    PubMedGoogle Scholar
  • 64 Okaro A C, Fennell D A, Corbo M et al.. Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-Xl and Mcl-1 expressing human cholangiocarcinoma cells.  Gut. 2002;  51 556-561
    CrossrefPubMedGoogle Scholar
  • 65 Nzeako U C, Guicciardi M E, Yoon J H, Bronk S F, Gores G J. COX-2 Inhibits Fas-mediated apoptosis in cholangiocarcinoma cells.  Hepatology. 2002;  35 552-559
    CrossrefPubMedGoogle Scholar
  • 66 Lai G H, Zhang Z, Sirica A E. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced akt inactivation and increased activation of caspases-9 and -3.  Mol Cancer Ther. 2003;  2 265-271
    PubMedGoogle Scholar
  • 67 Yoon J-H, Werneburg N W, Higuchi H et al.. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism.  Cancer Res. 2002;  62 6500-6505
    PubMedGoogle Scholar
  • 68 Buys C. Telomeres, telomerase, and cancer.  N Engl J Med. 2000;  342 1282-1283
    CrossrefPubMedGoogle Scholar
  • 69 Shay J W, Bacchetti S. A survey of telomerase activity in human cancer.  Eur J Cancer. 1997;  33 787-791
    CrossrefPubMedGoogle Scholar
  • 70 Bryan T M, Cech T R. Telomerase and the maintenance of chromosome ends.  Curr Opin Cell Biol. 1999;  11 318-324
    CrossrefPubMedGoogle Scholar
  • 71 Ozaki S, Harada K, Sanzen T et al.. In situ nucleic acid detection of human telomerase in intrahepatic cholangiocarcinoma and its preneoplastic lesion.  Hepatology. 1999;  30 914-919
    CrossrefPubMedGoogle Scholar
  • 72 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorgenesis.  Cell. 1996;  86 353-364
    CrossrefPubMedGoogle Scholar
  • 73 Benckert C, Jonas S, Cramer T et al.. Transfoming growth factor beta 1 stimulates vascular endothelial growth factor gene transcrtiption in human cholangiocellular carcinoma cells.  Cancer Res. 2003;  63 1083-1092
    PubMedGoogle Scholar
  • 74 Ashida K, Terada T, Kitamura Y, Kaibara N. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study.  Hepatology. 1998;  27 974-982
    CrossrefPubMedGoogle Scholar
  • 75 Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.  Hepatology. 1996;  23 1341-1344
    CrossrefPubMedGoogle Scholar
  • 76 Lavaissiere L, Jia S, Nishiyama M et al.. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma.  J Clin Invest. 1996;  98 1313-1323
    PubMedGoogle Scholar
  • 77 Ince N, de la Monte S, Wands J R. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation.  Cancer Res. 2000;  60 1261-1266
    PubMedGoogle Scholar
  • 78 Maeda T, Sepe P, Lahousse S et al.. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells.  J Hepatol. 2003;  38 615-622
    CrossrefPubMedGoogle Scholar
  • 79 Tanaka S, Sugimachi K, Kameyama T et al.. Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma.  Hepatology. 2003;  37 1122-1129
    CrossrefPubMedGoogle Scholar
  • 80 Kireeva M L, Mo F E, Yang F P, Lau L F. Cyr61, a product of growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion.  Mol Cell Biol. 1996;  16 1326-1334
    PubMedGoogle Scholar

Jack WandsM.D. 

Liver Research Center, Rhode Island Hospital

593 Eddy Street, APC, 421

Providence, RI 02903

Email: jack_wands_md@brown.edu

      >